ET-600 is an innovative product candidate under development for the treatment of an endocrinology condition that is estimated to impact less than 5,000 pediatric patients in the U.S. If approved, ET-600 is expected to be a patent-protected, durable product that can generate significant long-term revenue and profit for the company.
Bill Gates Says He Loves Learning About This Topic And Shares ‘Cool Research’ Being Conducted
Microsoft Corporation (NASDAQ: MSFT) co-founder Bill Gates recently took to Twitter to share an article published in the Harvard M
